Sepsis Clinical Trial
Official title:
Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy (PCNL)
To evaluate whether 5 days of levofloxacin before percutaneous nephrolithotomy (PCNL) in reducing upper urinary tract infection and urosepsis after PCNL.
Percutaneous nephrolithotomy (PCNL) is a minimally invasive procedure for removal of large
volume upper urinary tract stones. Although PCNL is effective and yielding high stone-free
rates, complications rates range from 18.30% to 83% with sepsis has been reported in 0.3% to
7.6% of cases result in the most common cause of perioperative mortality in PCNL patients.
Urosepsis after PNL is an important and potentially catastrophic complication. The overall
incidence of fever (25%), bacteremia (23%), endotoxemia (34%) and septicemic shock occurs in
0.3%-2.5% of patients. Urosepsis and shock result from the intravasation of bacteria or
endotoxins into bloodstream, which in turn increases with prolonged surgery, degree of
hydronephrosis, bacterial load in the renal pelvis, and presence of infected stones.
Charton et al., concluded that without antibiotic prophylaxis 35% of patient suffered
urinary tract infection a post-PCNL, although preoperative urine showing no growth. In a
prospective but nonrandomized assessment of PCNL patients receiving oral ciprofloxacin,
intravenous ciprofloxacin, or no antimicrobial treatment found postoperative urinary tract
infection to occur in 17%, 0%, and 40% of patients, respectively. Mariappan et al., stated
that midstream urine (MSU) culture does not represent upper tract infection in patients with
obstructing stones. Also, stone and pelvic urine cultures are better predictors of upper
tract infection and urosepsis in such cases.
Antibiotic prophylaxis has been recommended (Level of evidence: IIb, III) for patients
subjected to PCNL to avert these infectious complications, as profiled in an American
Urological Association (AUA) Best Practice Policy Statement. They also recommend antibiotic
prophylaxis before shock wave lithotripsy and ureteroscopy with high level (Level of
evidence: Ia and Ib, respectively) due to presence of meta-analysis and large randomised
controlled trial.
The optimal timing, dosing, and duration of a prophylactic antibiotic regimen for PCNL
procedures has also been a point of discussion. The AUA best practice policy statement
currently recommends that a one-time dose on the day of the procedure is sufficient. The EAU
guidelines are less definitive in concluding that a short course is adequate but that the
"length of time is to be determined." Mariappan and colleagues in a prospective
non-randomised trial found that 52 patients who had dilated collecting systems, stone burden
greater than 2 cm, and no confounding factors predisposing to UTIs who received a 1-week
course of ciprofloxacin before PCNL had a 3-fold lower risk of postoperative UTI and SIRS
than 46 patients who received standard perioperative antibiotics on the day of surgery.
Bag and colleagues prospectively randomized 101 patients with greater than 2.5-cm kidney
stones and/or hydronephrosis with sterile preoperative urine cultures to a 7-day course of
nitrofurantoin versus no antibiotics before PCNL and found a statistically significant lower
rate of postoperative SIRS (19% vs 49%), endotoxemia (18% vs 42%), positive result on kidney
urine culture (0% vs 10%), and positive result on stone culture (8% vs 30%) in the arm
receiving nitrofurantoin.
Although these two small series support a week of preoperative antibiotics before PCNL,
larger, prospective, randomized studies are needed to better elucidate the risks and
benefits of empiric antibiotics
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |